Free Trial

ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis

+0.17 (+1.13%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.62 million shs
Average Volume
1.80 million shs
Market Capitalization
$2.52 billion
P/E Ratio
Dividend Yield
Price Target

ACADIA Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
89.5% Upside
$28.94 Price Target
Short Interest
7.28% of Shares Sold Short
Dividend Strength
News Sentiment
0.32mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.63 M Sold Last Quarter
Proj. Earnings Growth
From $0.57 to $1.01 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.00 out of 5 stars

Medical Sector

180th out of 921 stocks

Pharmaceutical Preparations Industry

71st out of 416 stocks

ACAD stock logo

About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACAD Stock Price History

ACAD Stock News Headlines

ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 52-Week Low at $14.68
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
16 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$726.44 million
Book Value
$2.63 per share


Free Float
Market Cap
$2.52 billion
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

ACAD Stock Analysis - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ACAD shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price target for 2024?

16 equities research analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price targets range from $19.00 to $42.00. On average, they predict the company's share price to reach $28.94 in the next twelve months. This suggests a possible upside of 89.5% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2024?

ACADIA Pharmaceuticals' stock was trading at $31.31 at the start of the year. Since then, ACAD shares have decreased by 51.2% and is now trading at $15.27.
View the best growth stocks for 2024 here

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our ACAD earnings forecast

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.06. The biopharmaceutical company earned $205.83 million during the quarter, compared to the consensus estimate of $208.31 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 0.41% and a negative net margin of 0.21%. The company's revenue for the quarter was up 73.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.27) EPS.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $966.6 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.05%), Price T Rowe Associates Inc. MD (2.42%), Jupiter Asset Management Ltd. (0.97%), Rice Hall James & Associates LLC (0.40%), Nordea Investment Management AB (0.20%) and M&G Plc (0.19%). Insiders that own company stock include Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACAD) was last updated on 5/21/2024 by Staff

From Our Partners